AtriCure, Inc. develops, manufactures, and sells devices for surgical ablation of cardiac tissue, exclusion of the left atrial appendage, and temporarily blocking pain by ablating peripheral nerves to medical centers in the United States, the Asia-Pacific, and internationally. The company offers Isolator Synergy Clamps, a single-use disposable radio frequency products; multifunctional pens and linear ablation devices, a single-use disposable RF products for the treatment of cardiac arrhythmias; cryoICE Cryoablation System that enables the user to make linear ablations of varied lengths; and EPi-Sense Systems, a single-use disposable device used for the treatment of symptomatic, drug-refractory, and long-standing persistent atrial fibrillation. It also provides cryoSPHERE probe, which provides temporary pain relief by applying cryothermic energy to targeted intercoastal peripheral nerves in the ribcage; AtriClip System, an implantable device coupled to a single-use disposable applier; LARIAT System, a solution for soft-tissue closure; Lumitip dissectors to separate tissues to provide access to key anatomical structures that are targeted for ablation; Glidepath guides for placement of clamps; and Subtle Cannula's to support access for EPi-Sense catheters. In addition, the company sells various reusable cardiac surgery instruments. It markets and sells its products through independent distributors and direct sales personnel. The company was incorporated in 2000 and is headquartered in Mason, Ohio.

AtriCure Inc.

In a report released today, Rick Wise from Stifel Nicolaus maintained a Buy rating on Atricure, with a price target of $50.00. The company’s shares...

Stifel Nicolaus Keeps Their Buy Rating on Atricure (ATRC)

Atricure, Inc. (($ATRC)) announced an update on their ongoing clinical study. Study Overview: AtriCure, Inc. is conducting a multicenter patient re...

AtriCure’s Ongoing Study: Implications for Cardiac Treatment and Market Performance

Atricure, Inc. (($ATRC)) announced an update on their ongoing clinical study. Study Overview: The clinical study titled ‘Cryo NerVe Block Extremity...

Current Quarter	$-0.04	Next Quarter	$-0.1
Current Year	$-0.23	Next Year	$-0.09
QoQ Growth	-150.0%	YoY Growth	+60.9%
3Y EPS CAGR	-41.9%	Target Price	$51.44
Consensus	Buy	Upside	+42.2%

Current Quarter Rev	N/A	Next Quarter Rev	N/A
Revenue Growth	N/A	YoY Growth	N/A

	A	B	C	D
1	Symbol	Price	Change	Volume
2	ATRC	$36.17	+8.78%	571.22K
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	ATRC	$36.17	+8.8%	571.22K
3
4
5
6

ATRC

ATRC

EPS Estimates Overview

EPS Historical Trend (5 Years)

Quarterly EPS Estimates

Revenue Analysis

Get AtriCure Inc. Data in Excel

Get AtriCure Inc. Data in Excel